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EDUCATIONAL AIMS
 To provide an overview of the potential, limitations and difﬁculties of using nanoparticles in various imaging modalities.
 To discuss the use of nanoparticles as both diagnostic and therapeutic agents.
 To understand that nanoparticles can be actively or passively targeted, or used as intracellular agents to track living cells.
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S U M M A R Y
This review will provide an overview of current research into lung imaging with nanoparticles, with a
focus on the use of nanoparticles as molecular imaging agents to observe pathological processes and to
monitor the effectiveness of nanoparticulate drug delivery systems. Various imaging modalities together
with their advantages and limitations for lung imaging will be discussed. We will also explore the range
of nanoparticles used, as well as active or passive targeting of nanoparticles.
 2011 Elsevier Ltd. All rights reserved.
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Paediatric Respiratory ReviewsINTRODUCTION
Nanoparticles can act as a contrast agent in medical imaging in
order to enhance the difference between normal and diseased tissue.
Over the past decade, research into nanoparticles for imaging and
drug delivery has increased rapidly.1 This may be partly due to
improvements in sensitivity of imaging instrumentation but also
due to increasing appreciation of their potential utility. A
nanoparticle is described by the National Nanotechnology Initiative
as being any material having one or more dimension in the
nanoscale (0–100 nm). The advantage of using nanoparticles over
small molecular weight contrast agents is their ability to deliver a
large payload of contrast material, targeting moieties, drugs or
nucleic acids per particle. Nanoparticles may also have signiﬁcantly
different pharmacokinetics and pharmacodynamics to low mole-
cular weight compounds, and altering their physicochemical
properties can tailor biodistribution for tissue speciﬁc targeting.* Corresponding authors. UCL Centre for Advanced Biomedical Imaging, Paul
O’Gorman Building, 72 Huntley Street, London, WC1E 6DD.
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doi:10.1016/j.prrv.2011.07.001This review will discuss recent advances in the ﬁeld of imaging
nanoparticles for the investigation of pathology and monitoring
drug delivery. Although the development of nanoparticulate
contrast agents for pulmonary imaging is very much in its infancy,
imaging lung disease in the clinic or in preclinical models can be
achieved through various modalities, for example, nuclear
medicine, CT (computed tomography), optical imaging or MRI
(magnetic resonance imaging).
The only nanoparticle with FDA approval for clinical use in
imaging is the superparamagnetic iron oxide nanoparticle (SPIO)
EndoremTM, used in MRI diagnosis of liver tumours and metastases,
although this is no longer manufactured.2 However, there are
many different types of nanoparticles in development for imaging.
These include superparamagentic or paramagnetic nanoparticles,3
liposomes,4 carbon nanotubes,5 micelles6 and quantum dots.7
Lung Imaging
Delivering contrast agents to pulmonary tissue can be achieved
by inhalation or by intravenous injection. Delivering agents though
the airways may offer advantages when the aim is to target lung
tissue. The alveoli provide a large surface area for drug absorption,
and the single cell layer of the epithelium allows easier penetration
of compounds into the vasculature.8,9 Conversely, clearance of
agents from the lungs can be rapid due to its high vascularity,10
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retention rather than absorption of nanoparticle.
Yet the challenges do not just lie with the design of the
nanoparticles. Respiratory and cardiac motion leads to imaging
artefacts and corruption of the images. To overcome these
problems images can be acquired during a breath hold, although
this technique is impractical for very young children. Another
method is to use respiration image gating, where images are
acquired at speciﬁc points in the breathing cycle.11
Despite these problems, which are applicable to all imaging
modalities, each method has its own speciﬁc qualities. MRI offers
distinct advantages over the nuclear imaging modalities in terms
of the achievable spatial resolution, and over both CT and nuclear
imaging as it uses non-ionising radiation, although its sensitivity is
limited. This is especially important in paediatric patients and
those needing repeated follow-up scans. The use of nanoparticu-
late contrast agents for imaging modalities holds much potential
for the early detection of various diseases in the lung including
obstructive lung diseases, cystic ﬁbrosis and cancer.
MAGNETIC RESONANCE IMAGING
Imaging the lung using proton magnetic resonance imaging is
notoriously difﬁcult. Multiple airspaces restrict the tissue density
within a MRI voxel, dramatically reducing the signal intensity. This
is further exacerbated by rapid dephasing of magnetisation;
shortening T2, the MRI transverse relaxation time of the tissue.
This rapid dephasing of magnetisation is a result of multiple air-
tissue interfaces (there is a very high surface area to volume ratio of
the lung tissue). Therefore conventional MRI sequences may have
very limited sensitivity to contrast agents that employ negative
contrast (i.e. reduce the measured signal) due to the very low
baseline signal. There have been considerable efforts to improve
lung MRI to overcome these challenges.
Lung MRI Advances
In order to increase the measured signal, specialised MRI
techniques have been developed. An important example is ultra-
short echo-time (UTE) imaging.12 This is a specialised pulse
sequence that detects signal rapidly, before it quickly decays due to
T2 and has recently become possible due to advances in MRI
gradient hardware and MRI physics innovations.13 The increase in
signal enables visualisation of lung parenchyma, allowing assess-
ment of lung architecture and possible diagnosis of pathology.12,14
An alternative approach to improving image quality is balanced
steady-state free precession (SSFP), however lung imaging using
this technique has primarily been employed using low ﬁeld MRI
scanners (0.2T),15 which are not typically found in the most
hospitals. Importantly, by employing UTE or SSFP to enhance the
signal, contrast agents that produce local decreases in signal can be
detected.
Hyperpolarised gas MRI can provide a ten thousand to one
hundred thousand fold increase in signal16 and has produced
impressive images of lungs in patients.17 This can provide accurate
information on lung function that global spirometry measures
cannot. For a detailed recent review on the subject of estimating
functional parameters such as perfusion and ventilation using
imaging techniques see Ohno et al.18
As previously mentioned, there is limited use of nanoparticles
in MRI in the adult population, let alone the paediatric arena.
However, nanotechnology has been increasingly developed and
applied in preclinical medical imaging over the past decade. In–
icular, superparamagnetic iron oxide nanoparticles (SPIO) are well
suited as an MRI contrast agent and thus will be the focus of this
section.Superparamagnetic Iron Oxide Nanoparticles (SPIO)
Magnetic nanoparticles offer attractive possibilities in biomedi-
cine as an MRI contrast agent and also for other applications, such as
magnetic separation, hyperthermia therapy for cancer and drug
delivery.19 A key advantage of SPIOs is that their sizes can be
accurately controlled during manufacture over a wide range, to
reﬂect dimensions that are smaller than or comparable to those of a
cell (10–100 mm), a virus (20-450 nm), a protein (5–50 nm) or a
gene (2 nm wide and 10–100 nm long).19 Thus, they can be
incorporated into cells affording a controllable means of ‘tagging’.
Importantly, MRI relaxation times are shortened by the use of
magnetic contrast agents, which enables imaging of these particles.
The most common MRI contrast agents currently used are the
paramagnetic gadolinium ion complexes, although agents based
on superparamagnetic nanoparticles have been commercially
available. The superparamagnetic iron oxide (SPIO) particles are
magnetically saturated in the normal range of magnetic ﬁeld
strengths used in MRI scanners, thereby establishing a substantial
locally perturbing dipolar ﬁeld which leads to a marked shortening
of T2, leading to local hypointensities in an image and the
possibility of imaging the localisation of these particles. However,
given the extremely short T2 in the lung, the use of super-
paramagnetic contrast agents to enhance this further may be less
applicable in the lung than it is to other organs.
Actively Targeted Nanoparticles for MRI
In order to overcome the problem of short T2 in the lung,
hyperpolarised helium gas MRI has been used in conjunction with
actively targeted iron oxide nanoparticles. The hyperpolarised
helium increases the signal strength in the lung20 and enhances the
detection of the signal hypointensity caused by the nanoparticles.
SPIOs functionalized with luteinizing hormone–releasing hormone
(LHRH) have been used with hyperpolarised helium gas MRI to
speciﬁcally target pulmonary micro-metastases which, due to
their size, could not be imaged by PET or SPECT21. The
micrometastases were visible after SPIO injection due to the
signal voids they created in the hyperpolarised helium gas.
Passive Targeting of Nanoparticles
Despite the limited use of targeted nanoparticles, SPIOs are
readily used to image preclinical models of cancer, taking advantage
of the passive targeting to tumours that can be achieved with
systemic injection. Once tumours reach a certain size, new blood
vessel formation, or angiogenesis is required for further growth.
These new vessels are poorly structured and irregular, allowing
leakage of blood plasma components, including nanoparticles, into
the tumour. Once inside the tumour, they are retained for longer
periods of time due to poor lymphatic and venous drainage. This
phenomenon is known as the enhanced permeability and retention
effect (EPR) and allows passive targeting of nanoparticles into
tumours.22 Once inside the tumour, the nanoparticles produce
signal loss and hence, contrast between tumour and normal tissue.
This has lead to preclinical applications of SPIO for imaging tumours
and metastases. For example, Jain et al. have developed pluronic
coated nanoparticles that enhance contrast in the tumour, and could
also be loaded with anti-cancer agents.23
Cell tracking and therapies
Another interesting property of SPIOs is their ability to label
cells for MRI tracking. Mesenchymal stem cells (MSCs) can be
easily extracted from a patient with a bone marrow biopsy, and
expanded in culture for injection back into the body as an
Figure 1. High-resolution lung MR images showing lung metastases (circled) pre- and post-MSC delivery. The MSCs contain SPIO, therefore after MSC delivery the metastases
become dark. Adapted and reprinted by permission from the American Association for Cancer Research. Loebinger et al. Magnetic resonance imaging of mesenchymal stem
cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Research, 69(23); 8862-8867.
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endocytosis, with little effect on cell survival or proliferation.24 It is
well known that MSCs have the ability to home to and incorporate
into areas of inﬂammation and injury within the body.25 Therefore,
SPIO can be utilised to track these labelled MSCs using MRI.
In a recent preclinical study, SPIO labelled MSCs have been
tracked homing to pulmonary metastases using MRI (Figure 1).26
This ability to visualise both primary tumours and metastases
using SPIO labelled MSCs and MRI is obviously of great beneﬁt for
cancer staging and diagnosis. MSCs are also being used as vectors
to carry anti-cancer therapies to tumours.27 Combining these
applications will allow MRI tracking of cell therapies being
delivered to tumours. Although much of this work has been done
in lung cancer models, it may also be applicable to any disease
process inducing inﬂammation within the lung.
There is currently a lot of interest in using stem cells for the
repair of airway injury28 and as vectors for the delivery of drugs or
therapeutic genes into a targeted area.29 Labelling these engi-
neered MSCs with SPIO before injection would allow tracking to
the site of interest and quantiﬁcation of the efﬁciency of cell
delivery.30 Combined with MR imaging, this developing ﬁeld could
see MRI tracked cell therapy aimed at common respiratory
diseases in childhood, for example gene therapy for cystic ﬁbrosis.
Summary
Preclinical MR imaging with nanoparticles is a rapidly
expanding ﬁeld. SPIO nanoparticles are becoming ever more
complex, functionalised with therapeutic or targeting agents.
However, it could take many years before these experimental
nanoparticles are translated into paediatric clinical applications.
NUCLEAR MEDICINE
The nuclear imaging modalities do not suffer from the same
sensitivity problems as MRI. The major issue in the nuclear
modalities is background signal caused by non-speciﬁc organuptake or prolonged circulation of the radiotracer in blood. There is
therefore much interest in designing high-afﬁnity radiotracers
with improved biodistribution, targeted to markers of angiogen-
esis or inﬂammation as this could enable earlier detection of
pathology.31 Nanoparticles are attractive for this purpose as they
can be modiﬁed to carry radioisotopes on their surface coatings.
Although there are currently no nanoparticulate radiotracers in
clinical use, radiolabelled nanoparticles are being increasingly
used in preclinical studies of inﬂammation and cancer.
Targeted imaging agents for nuclear medicine
The use of coated nanoparticles with a targeting ligand or
antibody can provide enhanced tissue targeting and speciﬁcity. For
example, integrins such as avb3, avb5, and a5b1 are often highly
expressed on tumour vasculature and have a low background
expression in normal tissue, rendering them ideal targets for
molecular imaging probes. For example, Lee et al. have demon-
strated the possibility of using combined PET/MR imaging of
bifunctional iron oxide nanoparticles labelled with radioactivity
and tumour targeting integrin avb3
32. This bimodal approach
could be advantageous due to the recent commercialisation of dual
modality PET/MRI scanners.
Latex nanoparticles conjugated to monoclonal antibodies
speciﬁc to intercellular adhesion molecule 1 (ICAM-1) have been
radiolabelled for PET imaging appear to be speciﬁc to the lung
endothelium33. In this study a systemic lipopolysaccharide (LPS)
insult led to increased nanoparticle retention in pulmonary tissue
at 24 hours post injection, probably due to the high vascularity of
lung tissue compared with other organs, leading to favourable
pharmokinetics. The authors suggest that the nanoparticles could
be used to monitor inﬂammation of lung disease, because ICAM-1
is upregulated by pathological processes.
Radiolabelled nanoparticles can be administered intravenously,
or via inhalation. In order to speciﬁcally deliver drugs and imaging
agents to the lungs it is possible to deliver them via an aerosol. This
method can improve the efﬁcacy of anti-cancer drugs in models of
Figure 2. Whole-body SPECT/CT carried out immediately after tail-vein injection of glycosylated Na125I carbon nanotubes compared to injection of Na125I. These
functionalised carbon nanotubes show remarkably speciﬁc lung accumulation. Reprinted by permission from Macmillan Publishers Ltd: [Nature Materials 2010;9(6):485–
90], copyright 2010.
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reduction in tumour volume using a paclitaxel aerosol in mice.34
Targeting the lungs directly via inhalation can result in much
better delivery and retention of nanoparticles.35 Videira et al. have
used solid lipid radiolabeled nanoparticles to track delivery and
clearance within the lungs of rats using a SPECT system.36 Inhaled
nanoparticles were delivered to small airways, where they were
taken up by the lymphatic system through the alveolar spaces.
They proposed the use of radiolabelled solid lipid nanoparticles for
lymphoscintigraphy or for monitoring drug delivery.
Carbon nanotubes
Single-walled carbon nanotubes (SWNTs) consist of a single
atomic layer of graphite rolled into a cylinder and consequently
they have unusual physical properties, such as electrical con-
ductance, thermal conductivity and luminescence.5 Recently, there
has been interest in using them for imaging applications as
radioemitting atoms or paramagnetic ions can be encapsulated
into SWNTs. Glycosylated nanotubes encapsulating Na 125I radio-
active atoms have been shown to accumulate in lungs with
remarkable speciﬁcity and stability in mice (Figure 2).37 Tissue
histology 30 days after dose showed no necrosis or ﬁbrosis in the
lung, or any other organ, but there are still concerns about the
safety of using such materials in patients.38 Carbon nanotubes
longer than 20 mm are expected to cause ﬁbrosis, pleural
thickening and mesothelioma (similar to asbestos ﬁbres), while
shorter nanotubes may be phagocytosed and cleared by macro-
phages, although the speciﬁc relationship between nanotube
length and toxicity has not yet been fully investigated.39
Monitoring drug delivery
Nanoparticles can be labelled with a radioactive probe in order
to track their progress in vivo. This can be done with direct labelling
techniques, or by using a ligand to attach the radioactive molecule
to the nanoparticle. The advantage of using radiolabelled
nanoparticles for SPECT or PET, is that they allow quantitative
assessment of nanoparticle delivery, with a high sensitivity.31 In
preclinical systems concentrations of radiotracer in the picomolar
range can be imaged at resolutions below 1 mm. This can be
measured repeatedly over a deﬁned period of time, depending onthe biodistribution and clearance of the nanoparticle, and the
radioactive half-life of the radiolabel. It is also possible to achieve
high activities of radiolabeled nanoparticles by attaching more
than one molecule of radioactive isotope to the nanoparticle,
which means they can be given at lower doses.40 This allows
quantitative assessment of nanoparticle delivery, and can be used
to monitor delivery of ‘theranostic’ drug-nanoparticle complexes,
which can be used for diagnosis and therapeutics. Chang et al. have
successfully shown delivery and therapeutic efﬁcacy of their 188Re
labelled Doxirubicin liposome for SPECT imaging and treatment of
murine colorectal carcinomas.41
COMPUTED TOMOGRAPHY (CT)
X-ray CT uses multiple x-ray projections to form a single 3D
image. Endogenous contrast is provided by the different x-ray
attenuation properties of air, tissue and bone. Exogenous contrast
agents include barium and iodinated compounds. These commonly
used contrast agents have high densities and are hence radio-
opaque in CT images. However, there are no nanoparticles in
clinical use as contrast agents for CT imaging and very few
preclinical studies exploring this.
The most commonly used nanoparticle in preclinical CT studies
are gold particles. They have a high atomic number and density,
which provides a 3-fold improvement in contrast over conven-
tional iodine contrast agents.42 These particles have been shown to
accumulate in tumours due to the enhanced permeability and
retention effect, indicating a potential use in tumour imaging.42 In
a different approach, Aillon et al. have used aerosolized nano-
particles in a preclinical CT imaging study to increase contrast in
the lungs.43 These nanoparticles were formulated from a derivative
of diatrizoic acid, an iodinated compound, and agglomerated to
produce nanoclusters of diameter 1-5 mm, suitable for deposition
in the lung periphery. They observed good enhancement of the
airways, with no acute toxic effects on lung tissue (no alveolar
tissue damage or inﬂammation within the lungs 2 hours after
dosing).
CONCLUSION
Nanoparticles show great potential as contrast agents to
enhance diagnostic imaging of the lungs. Nanoparticles are already
K.L. Ordidge et al. / Paediatric Respiratory Reviews 13 (2012) 84–8888used for drug delivery applications and for MR imaging. They are
also extensively used in preclinical studies with both MR imaging
and nuclear imaging. Nanoparticles for multimodal imaging, and
for combined diagnosis and therapy, is a rapidly developing area.
Combining this imaging expertise with nanoparticle based drug or
gene delivery systems will allow monitoring of therapies in vivo.
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